IMAB027 (ASP1650): A Comprehensive Report on a Claudin 6-Targeting Monoclonal Antibody

I. Introduction to IMAB027

A. Overview and Identification

IMAB027 is an investigational monoclonal antibody (mAb) specifically developed to target Claudin 6 (CLDN6), a protein that shows aberrant expression in a variety of human cancers.[1] This therapeutic agent is also widely recognized by the synonym ASP1650, particularly in documentation related to its development by Astellas Pharma.[1] The DrugBank identification number assigned to IMAB027 is DB17282, indicating its status as a cataloged investigational drug.

As a biopharmaceutical product, IMAB027 falls under the category of biotech drugs, leveraging biological systems for its production and therapeutic effect. The molecular weight of this antibody is approximately 144.42 kDa [1], typical for an IgG class monoclonal antibody. The Chemical Abstracts Service (CAS) Registry Number for IMAB027 is 1650599-68-0.[1]

The dual nomenclature, IMAB027 and ASP1650, is indicative of its developmental history. "IMAB" likely stems from Ganymed Pharmaceuticals' "Ideal Monoclonal Antibody" platform, the originating company, while "ASP" is a common prefix for compounds developed by Astellas Pharma. This naming pattern often signifies a transition in the drug's development, such as a partnership or acquisition, which in this case was the acquisition of Ganymed by Astellas.[2] The assignment of a DrugBank ID suggests that IMAB027 has undergone significant preclinical characterization and has progressed into clinical investigation.

B. Classification and Antibody Type